60+ Genes Tested FDA-Approved Targeted Therapies & Gene Indicators

60+ genes tested

ABL1, ABL2, ALK, AR, ARAF, ATM, ATR, BRAF, BRCA1*, BRCA2*, BTK, CCND1, CCND2, CCND3, CDK4, Somatic mutation detection CDK6, CDKN1A, CDKN1B, CDKN2A, CDKN2B, DDR1, DDR2, EGFR, ERBB2 (HER2), ESR1, FGFR1, FGFR2, for approved cancer therapies FGFR3, FGFR4, FLCN, FLT1, FLT3, FLT4, GNA11, GNAQ, HDAC1, HDAC2, HRAS, JAK1, JAK2, KDR, KIT, in solid tumors KRAS, MAP2K1, MET, MTOR, NF1, NF2, NRAS, PALB2, PARP1, PDGFRA, PDGFRB, PIK3CA, PIK3CD, PTCH1, PTEN, RAF1, RET, ROS1, SMO, SRC, STK11, TNK2, TSC1, TSC2

FDA-approved Targeted Therapies & Gene Indicators

Abiraterone AR Necitumumab EGFR

Ado-Trastuzumab ERBB2 (HER2) Nilotinib ABL1, ABL2, DDR1, DDR2, KIT, PDGFRA, PDGFRB Emtansine FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, Afatinib EGFR, ERBB2 (HER2) Nintedanib PDGFRB Alectinib ALK Olaparib ATM, ATR, BRCA1*, BRCA2*, PALB2, PARP1 Anastrozole ESR1 Osimertinib EGFR Axitinib FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB CDK4, CDK6, CCND1, CCND2, CCND3, CDKN1A, Palbociclib Belinostat HDAC1, HDAC2 CDKN1B, CDKN2A, CDKN2B Panitumumab EGFR Bicalutamide AR Panobinostat HDAC1, HDAC2 Bosutinib ABL1, SRC Pazopanib FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB Cabozantinib FLT1, FLT3, FLT4, KDR, KIT, MET, RET Pertuzumab ERBB2 (HER2) Ceritinib ALK ABL1, FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT3, FLT4, Cetuximab EGFR Ponatinib KDR, KIT, PDGFRA, PDGFRB, RET, SRC Cobimetinib MAP2K1 Ramucirumab KDR Crizotinib ALK, MET, ROS1 Regorafenib ARAF, BRAF, FLT1, FLT4, KDR, KIT, PDGFRB, RAF1, RET Dabrafenib BRAF Ruxolitinib JAK1, JAK2 Dasatinib ABL1, ABL2, DDR1, DDR2, SRC, TNK2 Sonidegib PTCH1, SMO Enzalutamide AR ARAF, BRAF, FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB, Sorafenib Erlotinib EGFR RAF1, RET

FLCN, MTOR, NF1, NF2, PIK3CA, PTEN, STK11, TSC1, Sunitinib FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET Everolimus TSC2 FLCN, MTOR, NF1, NF2, PIK3CA, PTEN, STK11, TSC1, Temsirolimus Exemestane ESR1 TSC2

Fulvestrant ESR1 Toremifene ESR1

Gefitinib EGFR Trametinib GNA11, GNAQ, HRAS, KRAS, MAP2K1, NRAS

Ibrutinib BTK Trastuzumab ERBB2 (HER2)

Idelalisib PIK3CD Vandetanib EGFR, FLT1, FLT4, KDR, RET

Imatinib ABL1, DDR1, DDR2, KIT, PDGFRA, PDGFRB Vemurafenib BRAF

Lapatinib EGFR, ERBB2 (HER2) Vismodegib PTCH1, SMO

Lenvatinib FLT1, KDR Vorinostat HDAC1, HDAC2

Letrozole ESR1

*No germline inference can be made. CANCERPLEX TX covers the following genes conferring resistance to approved targeted therapies: KRAS, BRAF, NRAS and EGFR T790M. For the most up-to-date list of targeted, FDA-approved therapies, visit CANCERPLEX.com